A Phase i trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 355-362

  Gerecitano, John F ^a   Stephenson, Joe J ^b   Lewis, Nancy L ^c   Osmukhina, Anna ^d   Li, Jianguo ^d   Wu, Kaida ^d,e   You, Zhiping ^d   Huszar, Dennis ^d   Skolnik, Jeffrey M ^d   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Cancer Centers of the Carolinas   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d ASTRAZENECA   (United Kingdom)

^e R and D day   (United States)

Author keywords

AZD4877; Eg5; Pharmacokinetics; Safety; Solid tumors; Tolerability

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; KINESIN; KINESIN SPINDLE PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER RECURRENCE; CHILL; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HYDRONEPHROSIS; HYPOXIA; LUNG EMBOLISM; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; AGED; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KINESIN; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PYRIMIDINONES; TISSUE DISTRIBUTION;

EID: 84878171166     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9821-y     Document Type: Article

References (14)

1. Le Guellec R, Paris J, Couturier A, Roghi C, Philippe M (1991) Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein. Mol Cell Biol 11:3395-3398
2. Miki H, Okada Y, Hirokawa N (2005) Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 15:467-476
3. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971-974
4. Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, et al. (2004) Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 335:547-554
5. Huszar D, Theoclitou M-E, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer and Metastasis Reviews. 2009;28:197-208.
6. Pinzon-Ortiz M, Cao A, Sheehy A, Pablo L, McEachern K, Hylander-Gans L, et al. (2010) Characterization of the kinesin spindle protein inhibitor AZD4877. AACR Annual Meeting
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
8. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. (2007) Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 25:579-586
9. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, et al. (2012) A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 69:165-172
10. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, et al. (2011) A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 67:447-454
11. Holen K, Dipaola R, Liu G, Tan AR, Wilding G, Hsu K, et al. (2011) A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors. Investigational new drugs
12. Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, et al. (2011) A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Investigational new drugs 29:467-472
13. Esaki T, Seto T, Ariyama H, Arita S, Fujimoto C, Tsukasa K, et al. (2011) Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Archives of drug information 4:23-31
14. Gerecitano JF, O'Connor O, Deventer HV, Hainsworth J, Leonard J, Afanasayev B, et al. (2009) A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). J Clin Oncol p. 8578